Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02872142 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Plasma Exchange With Albutein® 5% in Participants With Amyotrophic Lateral Sclerosis
A Phase 2 study, sponsored by Grifols Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT02872142 is a Phase 2 study that has completed, run by Grifols Therapeutics. The registered enrollment target is 12 participants.
The verdict
NCT02872142, a Phase 2 study, has completed, sponsored by Grifols Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
This is a pilot, phase 2, prospective, open-label, single-arm study to evaluate disease progression, forced vital capacity, and the safety and tolerability of plasma exchange (PE) using Albutein® 5% in participants with amyotrophic lateral sclerosis (ALS).
Interventions
- PROCEDURE Plasma Exchange
- BIOLOGICAL Albutein 5%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2016-08-29 |
| Est. Completion | 2019-08-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02872142
The ClinicalTrials.gov registry entry for NCT02872142 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Grifols Therapeutics, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Plasma Exchange is the first listed.
NCT02872142 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02872142 about?
NCT02872142 is a clinical study titled "Efficacy and Safety of Plasma Exchange With Albutein® 5% in Participants With Amyotrophic Lateral Sclerosis". This is a pilot, phase 2, prospective, open-label, single-arm study to evaluate disease progression, forced vital capacity, and the safety and tolerability of plasma exchange (PE) using Albutein® 5% in participants with amyotrophic lateral sclerosis (ALS).
What is the current status of trial NCT02872142?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2016-08-29. Estimated completion is 2019-08-15.
What interventions are being tested in trial NCT02872142?
The interventions under investigation include: Plasma Exchange (PROCEDURE), Albutein 5% (BIOLOGICAL).
Who is sponsoring clinical trial NCT02872142?
This trial is sponsored by Grifols Therapeutics, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.